|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM283846321 |
| 003 |
DE-627 |
| 005 |
20231225041839.0 |
| 007 |
tu |
| 008 |
231225s2016 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0946.xml
|
| 035 |
|
|
|a (DE-627)NLM283846321
|
| 035 |
|
|
|a (NLM)29737646
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ullman, Kurt
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.06.2018
|
| 500 |
|
|
|a Date Revised 02.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Hepatitis B Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Thiazolidinediones
|2 NLM
|
| 650 |
|
7 |
|a Pioglitazone
|2 NLM
|
| 650 |
|
7 |
|a X4OV71U42S
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Diabetes self-management
|d 1998
|g 33(2016), 5 vom: 08. Sept., Seite 34, 37-8
|w (DE-627)NLM098190385
|x 0741-6253
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2016
|g number:5
|g day:08
|g month:09
|g pages:34, 37-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2016
|e 5
|b 08
|c 09
|h 34, 37-8
|